Skip to main content
. 2020 May 8;11:599. doi: 10.3389/fphar.2020.00599

Table 4.

Antiproliferative activity of compounds 1–16 in colon carcinoma cells HT-29P (parental), HT-29RNOV (multidrug resistance [MDR] phenotype), and HT-29RBD (multidrug resistance [MDR] phenotype).

Compound HT-29P HT-29RNOV HT-29RDB
IC50 ± SD (μM) IC50 ± SD (μM) RRa IC50 ± SD (μM) RRa
Epoxyboetirane E (2) > 50b 32.27 ± 4.69 < 0.65 47.21 ± 5.17 < 0.94
Epoxyboetirane N (6) > 100 48.92 ± 4.92 < 0.49 31.16 ± 0.53 < 0.31
Epoxyboetirane P (8) 8.24 ± 0.47 5.00 ± 0.16 0.61 5.25 ± 0.07 0.64
Epoxyboetirane R (10) > 50b 30.20 ± 4.05 < 0.60 > 50b
Methoxyboetirane B (15) 20.40 ± 1.83 9.40 ± 0.30 0.46 9.61 ± 0.10 0.47
Methoxyboetirane C (16) 17.20 ± 2.62 9.39 ± 0.37 0.55 13.12 ± 1.15 0.76
Cisplatin 3.8 ± 0.1 3.8 ± 0.1 1 2.7 ± 0.1 0.7
Etoposide 2.3 ± 0.3 35.0 ± 2.6 15.2 26.0 ± 1.7 11.3
DMSO (2%) > 100 > 100 > 100

aRelative resistance ratio, RR = IC50(resistant)/IC50(parental)); bAbove this concentration the compound crystallized in the culture medium. For all the other compounds, the IC50 was found to be above 100 µM, except for epoxyboetiranes M (5) and Q (9) which was above 25 µM – the maximum tested concentration due to lower water solubility. Each IC50 value indicates the mean ± SD of n = 3 to 4 independent experiments (each concentration was performed in triplicate per experiment).